Marker Therapeutics awarded $2.6 million FDA grant for pancreatic cancer program
The FDA awarded Marker Therapeutics a $2.6 million Orphan Products Development grant to advance MT-601 in pancreatic cancer.
Story updates
11:08:23 AM UTC
SquawkNews
Marker Therapeutics was awarded $2.6M by the FDA’s Orphan Products Clinical Trials program to support a Phase 1 study of MT-601 in locally advanced unresectable pancreatic cancer. The company expects study initiation in Q1 2027.Material DetailsContext by AI AnalystThis is an early-stage funding and…